Session » Osteoporosis & Metabolic Bone Disease Poster

Date: Friday, November 6, 2020

Time: 9:00AM-11:00AM

Meeting: ACR Convergence 2020

9:00AM-11:00AM: Abstract Number: 0106

A Machine Learning-derived Radiomics Nomogram for Diagnosis of Osteoporosis and Osteopenia

9:00AM-11:00AM: Abstract Number: 0125

A Resident-Led Interdisciplinary Quality Improvement Initiative to Increase Osteoporosis Screening in an Urban Clinic

9:00AM-11:00AM: Abstract Number: 0131

Analysis of the Total Body Composition in a Cohort of Patients with Elderly Onset Arthritis

9:00AM-11:00AM: Abstract Number: 0124

Appropriate Timing of Denosumab Dosing and Subsequent Therapy After Discontinuation: An Academic Medical Center Experience

9:00AM-11:00AM: Abstract Number: 0123

Aromatase Inhibitor-Associated Bone Loss: Screening and Prevention

9:00AM-11:00AM: Abstract Number: 0111

Assessment and Treatment of Glucocorticoid-Induced Osteoporosis in a Rheumatology Clinic

9:00AM-11:00AM: Abstract Number: 0121

Association of Low Bone Density with Need for Early Revision After Elective Joint Replacement for Osteoarthritis in Postmenopausal Women

9:00AM-11:00AM: Abstract Number: 0127

Biochemical Algorithm to Identify Individuals with ALPL Variants Between Subjects with Persistent Hypophosphatasaemia

9:00AM-11:00AM: Abstract Number: 0104

Bone Effects of One-year Tofacitinib Treatment in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 0102

Bone Health in Patients with Psoriatic Arthritis in the National Swiss Cohort: A Cross-sectional Study

9:00AM-11:00AM: Abstract Number: 0112

Description of Risk Factors at Baseline and Need of Bone Agent According to Hadji Recommendations in Patients Taking Aromatase Inhibitors as Breast Cancer Therapy

9:00AM-11:00AM: Abstract Number: 0117

Development of an In Vitro Trabecular Human Bone Model to Recapitulate Features of Glucocorticoid-induced Osteoporosis

9:00AM-11:00AM: Abstract Number: 0110

Does Urate Directly Influence Bone Turnover? Randomized Controlled Trial of Inosine Supplementation

9:00AM-11:00AM: Abstract Number: 0107

Effects of Abaloparatide on Modeling and Remodeling Based Bone Formation

9:00AM-11:00AM: Abstract Number: 0119

Fracture Liaison Service at an Academic Center with an Open Health System: 30-month Outcomes

9:00AM-11:00AM: Abstract Number: 0129

Glucocorticoid-Induced Osteoporosis in Patients with Chronic Inflammatory Rheumatic Diseases: A Multivariate Linear Regression Analysis Identifying Factors Affecting Bone Mineral Density

9:00AM-11:00AM: Abstract Number: 0109

Glucocorticoid-Induced Osteoporosis: Are We Practicing Prevention?

9:00AM-11:00AM: Abstract Number: 0126

Immunophenotyping of Peripheral Blood Highlights an Association of Dysregulated Lymphocytes with Patients with Glucocorticoid-induced Osteonecrosis

9:00AM-11:00AM: Abstract Number: 0113

Improving Glucocorticoid-Induced Osteoporosis Screening and Management in Patients with Rheumatic Diseases Using the 2017 ACR Guidelines

9:00AM-11:00AM: Abstract Number: 0115

Improving Osteoporosis Screening in Men at a Resident-run Primary Care Clinic: A Quality Improvement Project

9:00AM-11:00AM: Abstract Number: 0114

Incidence of Follow-Up Dual-Energy X-Ray Absorptiometry Scanner Error: A Contributor to Precision Error

9:00AM-11:00AM: Abstract Number: 0118

Indicators of Effectiveness After 6 Years of Follow-up in a Fracture Liaison Service

9:00AM-11:00AM: Abstract Number: 0122

Osteoporosis Medication Utilization Patterns over Time in the ACR RISE Registry

9:00AM-11:00AM: Abstract Number: 0133

Pharmacist-Driven Clinic Development for Patients with Incidental Vertebral or Hip Fractures

9:00AM-11:00AM: Abstract Number: 0132

Prevalence of Osteoporosis and Fragitlity Fractures Is Not Different Between ACPA Positive Patients Compared to ACPA Negative Patients in a Real World Setting, Despite Longer Disease Duration and Glucocorticoid-Treatment

9:00AM-11:00AM: Abstract Number: 0120

Risk of Fracture in Patients with Different Glucocorticoid Requiring Diseases

9:00AM-11:00AM: Abstract Number: 0101

Romosozumab After Denosumab Improves Lumbar Spine and Maintains Total Hip Bone Mineral Density in Postmenopausal Women with Low Bone Mass

9:00AM-11:00AM: Abstract Number: 0128

Short-Term Monitoring of Denosumab Effect in Breast Cancer Patients Receiving Aromatase Inhibitors Using Radiofrequency Echographic Multi-Spectrometry (REMS) Technology on Femoral Neck

9:00AM-11:00AM: Abstract Number: 0103

The Association of Methotrexate, Sulfasalazine and Hydroxychloroquine Use with Incident Fractures in Postmenopausal Women with Rheumatoid Arthritis: Findings from the Women’s Health Initiative

9:00AM-11:00AM: Abstract Number: 0116

The in Vitro 3D Fracture Gap Model: A Tool for Preclinical Testing

9:00AM-11:00AM: Abstract Number: 0130

The Prevalence of Osteoporosis in Individuals with Osteoarthritis: A Systematic Review

9:00AM-11:00AM: Abstract Number: 0108

The Relationship Between Body Fat Percentage and Bone Mineral Density in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 0105

Use of Peripheral Quantitative Computed Tomography in the Assessment of Bone Mineral Density in Anti-TNF-treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].